Watson’s generic version of Revatio is approved by US FDA

Hannah Blake

pharmaphorum

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg.

Sildenafil is the generic equivalent of Pfizer’s Revatio, which is indicated for the treatment of pulmonary arterial hypertension in adults, to improve exercise ability and delay clinical worsening. Revatio tablets had total US sales of approximately $339 million in the last year (ending September 30th 2012), according to IMS Health data.

Following approval in the United States, Watson plans to initiate shipping of its Sildenafil Tablets in the near future.

&nbsp,